Roth Capital Starts AcelRx Pharmaceuticals (ACRX) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/25/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Outlook Therapeutics (OTLK) halted, news pending
Jefferies Sees Zalviso Upside for AcelRx (ACRX) Following Pain Survey
April 16, 2014 6:58 AM EDTJefferies analyst Biren Amin reiterated a Buy rating and $17 price target on AcelRx Pharmaceuticals (NASDAQ: ACRX) following a physician survey which offered an optimistic upside scenario for Zalviso.
Amin commented, "We recently surveyed 43 physicians which currently prescribe IV patient-controlled analgesia to their... More
Jefferies Assumes AcelRx Pharmaceuticals (ACRX) at Buy
April 10, 2014 6:33 AM EDTJefferies assumes coverage on AcelRx Pharmaceuticals (NASDAQ: ACRX) with a Buy rating and a price target of $17.00 (from $15.00).
Analyst Biren Amin said, "We expect FDA approval of Zalviso, a treatment for moderate to severe pain in post-surgical patients, on its PDUFA Jul 27... More
